April 23, 2014

Specialty pharmacy operator Diplomat has access to dispense Arzerra, a cancer treatment with a recently expanded indication, the company noted Tuesday.

February 18, 2014

Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

January 20, 2014

The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e., cannot be removed by surgery) or metastatic (i.e., late-stage), Onco360 announced last week.

September 30, 2013

The Food and Drug Administration has approved a drug for treating early-stage breast cancer before surgery, the agency said Monday.

September 16, 2013

The Food and Drug Administration has approved a generic chemotherapy pill for treating colorectal and breast cancers, the agency said Monday.

June 10, 2013

Drug maker Amag Pharmaceuticals has licensed the U.S. commercial rights to a treatment for a common side effect of cancer treatments from another company, Amag said Monday.

October 26, 2012

A Swiss subsidiary of drug maker Celgene Corp. said its chemotherapy drug produced "significant" improvement in progression-free survival in patients with a deadly skin cancer that had spread elsewhere in the body.

October 22, 2012

A deal that would make a specialty pharmacy a distribution source for a new liquid chemotherapy drug may benefit breast cancer patients who have trouble swallowing pills.

September 28, 2012

Drug maker OncoGenex Pharmaceuticals has started its third late-stage clinical trial of a drug for treating a type of lung cancer.

September 11, 2012

Sagent Pharmaceuticals has launched a drug used to treat complications related to chemotherapy, the drug maker said.

August 6, 2012

The Food and Drug Administration has approved a new drug for treating colorectal cancer that has spread to other parts of the body, the agency said Friday.

July 9, 2012

The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.

April 3, 2012

Mylan has released a generic version of a drug used to treat a complication of certain chemotherapy regimens, the drug maker said Tuesday.

March 16, 2012

Pills for treating cancer have created numerous alternatives to spending hours in a clinic or at home receiving chemotherapy infusions, but risks of drug interactions remain, according to a new survey by the research arm of pharmacy benefit manager Medco Health Solutions.

February 15, 2012

Drug maker Biogen Idec plans to spend up to more than $560 million to buy a company developing treatments for organ failure.

January 30, 2012

The FDA announced the approval of Genentech's Erivedge (vismodegib) for adults with basal cell carcinoma who are not surgery or radiation therapy candidates and whose disease is locally advanced or has spread to other parts of the body.

November 7, 2011

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

August 19, 2011

The Food and Drug Administration has approved a new biotech drug for treating two types of lymphoma, the agency said Friday.

June 2, 2011

Bristol-Myers Squibb will collaborate with Roche to investigate the use of a combination of the companies’ drugs in patients with a deadly form of skin cancer.

April 27, 2011

An investigational drug helped patients survive longer when combined with chemotherapy as a second-line treatment for colorectal cancer that had spread to other parts of the body, according to results of a late-stage clinical trial announced by French drug maker Sanofi-Aventis and U.S.-based Regeneron Pharmaceuticals.

April 25, 2011

Drug maker AP Pharma has appointed two new executives and may receive financing of up to $4.5 million, the company said Monday.

March 25, 2011

The Food and Drug Administration has approved a new treatment for late-stage skin cancer, the agency said Friday.

March 24, 2011

Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

March 11, 2011

The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.